US Stock MarketDetailed Quotes
TRVI Trevi Therapeutics
- 2.640
- -0.260-8.97%
Close May 8 16:00 ET
- 2.610
- -0.030-1.14%
Post 18:24 ET
185.95MMarket Cap-7764P/E (TTM)
2.850High2.508Low116.74KVolume2.600Open2.900Pre Close307.59KTurnover0.29%Turnover RatioLossP/E (Static)70.44MShares4.00052wk High2.57P/B107.46MFloat Cap0.97052wk Low--Dividend TTM40.70MShs Float10.620Historical High--Div YieldTTM11.79%Amplitude0.460Historical Low2.634Avg Price1Lot Size
Trevi Therapeutics Stock Forum
Sign in to post a comment
$Trevi Therapeutics(TRVI.US$ Trevi Therapeutics Announces the Initiation of its Phase 2b CORAL Clinical Trial of Haduvio™ for Chronic Cough in Idiopathic Pulmonary Fibrosis (IPF) 2 MINUTES AGO, 7:30 AM EST VIA PR NEWSWIRE![]()
1
6
$Trevi Therapeutics(TRVI.US$ Trevi Therapeutics Announces Results from Phase 2b/3 PRISM Open-Label Extension Study of Haduvio™ in Prurigo Nodularis 5 MINUTES AGO, 8:30 AM EDT VIA PR NEWSWIRE TRVI SHARE Continued reduction in WI-NRS observed among participants who remained in the study through 52 weeks of treatment Safety data over 52 weeks: treatment was well tolerated and consistent with 14-week blinded safety data Preliminary analyses presented at the European Academy of Dermatology & V...
$Trevi Therapeutics(TRVI.US$ Long Buyers better Sell Off and enjoy your Gain 🤗👌👍, if greedy then check CS & BXRX 😏😩😪
$Trevi Therapeutics(TRVI.US$ Gap = Range = Bid & Ask >2 cents, it is no good to Trade 👉 Must be Deleted out of your Watchlist 👹👺👊
$Trevi Therapeutics(TRVI.US$
Test could not Short then Delete 😞
Test could not Short then Delete 😞
$Trevi Therapeutics(TRVI.US$ Ayer, el ensayo de fase 2b/3 (PRISM) de Trevi Therapeutics Inc (NASDAQ:TRVI) que evaluó Haduvio (nalbufina ER) para el prurigo nodular (PN) cumplió con éxito los criterios de valoración primarios y secundarios clave.
Needham escribe que Haduvio tuvo un inicio de acción rápido, alcanzando la estadística sig a las 6 semanas con una eficacia que aún no se había estancado en la lectura de la semana 14.
Trevi se reunirá con la FDA antes de iniciar un ensayo de fase 3 que...
Needham escribe que Haduvio tuvo un inicio de acción rápido, alcanzando la estadística sig a las 6 semanas con una eficacia que aún no se había estancado en la lectura de la semana 14.
Trevi se reunirá con la FDA antes de iniciar un ensayo de fase 3 que...
No comment yet
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
%Chg
Massinooo : Is this ticker good to trade?
TrytosaveabitOP Massinooo: It will be eventually! Im still looking for bottom?
Massinooo : I have it for 1.16 you think I should hold?
TrytosaveabitOP Massinooo: If you don’t mind averaging down some if need be? Im sorry! I just can’t say whether to buy or sell? I only say what I’m doing! I would hate to be responsible for someone losing! Grrr! Sorry but I’m rooting for you!
Massinooo : Totally understand bro. I’ll keep an eye on it after market opens and will decide. Thank you bro
View more comments...